Importantly, it should be noted that the anti-CXCL10 antibody treatment started before initiation of the disease by LCMV-infection and therefore like using CXCL10-deficient mice the CXCL10 neutralization constituted a preventive rather than a therapeutic intervention. The gene discussed is CXCL10; the disease is infection.